Therapeutic Asset Ratings

228 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Cyclophosphamide Immune Checkpoint Inhibitors	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Cyclophosphamide QL1706	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Dabrafenib BRAF V600E	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Dabrafenib Cetuximab	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Dabrafenib Dabrafenib	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Dabrafenib Ipilimumab N01	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Dabrafenib MSS (Microsatellite Stable)	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Dabrafenib Sintilimab	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
DALPICICLIB ISETIONATE Cell Cycle Deregulation	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
DALPICICLIB ISETIONATE EGFR Activating Mutation	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
DALPICICLIB ISETIONATE EGFR-TKI Resistant Mutation	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
DALPICICLIB ISETIONATE Late Frontline	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
DALPICICLIB ISETIONATE SHR-A1811	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Eloxatin Colorectal Cancer Liver Metastases (CRLM)	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Eloxatin Conversion Therapy	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Eparlitozoviril Hepatocellular Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Epirubicin Immune Checkpoint Inhibitors	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Epirubicin QL1706	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Famitinib Anlotinib	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Famitinib Aumolertinib	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Famitinib Li-Fraumeni Syndrome	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
FLUOROURACILUM Conversion Therapy	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Fluzoparib BRCA1/2 Mutation or Not	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Gtx-006 Late Frontline	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER SHR-A1811	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)

Showing 101 to 125 of 228 assets

PreviousPage 5 of 10Next